Veeva Systems Inc., based in the US, provides cloud solutions for the global life sciences industry. The company offers a range of cloud software, data, and business consulting services designed to meet the strategic needs of its customers from research and development (R&D) through commercialization. Veeva's offerings are categorized into three main product areas: Veeva Development Cloud, Veeva Commercial Cloud, and Veeva Data Cloud. Veeva Development Cloud includes application suites for clinical, regulatory, and safety functions within life sciences companies, all built on the Veeva Vault platform. Veeva Vault Clinical enhances clinical trial execution by offering a complete and connected technology ecosystem. Veeva Commercial Cloud comprises software and analytics solutions, including Veeva CRM, Veeva Vault PromoMats, Veeva Vault Medical, and Veeva Crossix. The data offerings under Veeva Data Cloud include Veeva OpenData, Veeva Link, and Veeva Compass.
The company has around 7,291 employees. Its geographical revenue distribution is as follows: North America accounts for 59%, Europe for 29%, Asia Pacific for 10%, and the Middle East/Africa/Latin America for 2%.
Veeva posts strong Q1 results
Veeva Systems released its Q1 26 results on May 28, 2025, with revenue up 16.8% y/y, reaching $759m, driven by subscription services revenues. EBIT rose by 46.3% to $234m, with margins expanding from 24.6% to 30.8%. Net profit increased by 41.4% to $229m. Notably, the company marked the seventh consecutive quarter surpassing analyst revenue expectations.
Enhanced research
On June 11, 2025, Veeva Systems announced that over 50 medtech companies, including 11 of the top 20 and seven of the top 10 medtech clinical research organizations (CROs), have adopted Veeva Clinical Platform applications to enhance medical device and diagnostics studies, enabling faster study build times and significant reductions in duplicate trial documents. In addition, on June 4, 2025, Veeva Systems and Sarah Cannon Research Institute (SCRI) revealed a strategic collaboration to improve oncology clinical trials across SCRI's 200+ research sites by unifying its CRO and SMO operations on Veeva Clinical Platform, facilitating seamless data flow and streamlined processes. This partnership aims to deliver groundbreaking therapies with enhanced precision and speed, driving innovation and cost-effective trials.
Veeva doubles cash from operations
Veeva Systems posted a robust revenue CAGR of 20% over FY 20-25, reaching $2,750m. EBIT surged at a CAGR of 19.5% over the same period, reaching $696m in FY 25, with a margin of 25.4%. Net income therefore rose at a CAGR of 18.9% to $714m in FY 25.
Cash from operations doubled from $437m to $1,090m over the same period. Cash and cash equivalent rose from $477m in FY 20 to $1,120m in FY 25. However, total debt also doubled from $54.8m to $75.8m in FY 25. Debt to equity of the company improved from 3.3% to 1.3%.
In comparison, Evolent Health, Inc., a local peer, reported a higher revenue CAGR of 30% over FY 19-24, reaching $2,550m. EBIT dropped at a CAGR of minus 52.3% to $2.3m. Net income also declined at a CAGR of minus 27.2% to minus $61.6m.
Looking ahead, analysts anticipate revenue CAGR of 12.5% over FY 25-28, reaching $3,912m. EBIT CAGR of 17.2% to $1,855m, with margins expanding from 41.9% to 47.4% in FY 28. In addition, analysts estimate a net profit CAGR of 17.4% to $1,156m with margins expanding by 355bp to 29.6% in FY 28, with EPS expected to increase to $6.7 in FY 28 from $4.3 in FY 25.
Stock delivers strong returns
Over the past one year, the company's stock has delivered an honorable return of approximately 56.8%, reflecting a positive fundamental trajectory. In comparison, Evolent Health delivered negative returns of about 40.3%.
Veeva Systems is currently trading at a P/E of 54.3x, based on the FY 26 estimated EPS of $5.2, which is lower than its 3-year historical average of 58.4x but higher than that of Evolent Health’s P/E of minus 11.8x. Likewise, in terms of EV/EBIT, the company is currently trading at 29.5x, based on the FY 26 estimated EBIT of $1,362m, which is lower than its 3-year historical average of 30.5x but higher than Evolent Health’s valuation of 16.5x.
Veeva Systems is liked by over half of the 29 analysts who monitor it; 12 have ‘Buy’ ratings, seven have ‘Outperform’ ratings, while 10 have ‘Hold’ ratings for an average target price of $292.4, although only implying 2.9% upside from its current level.
Overall, the company continues to demonstrate strong performance and growth, driven by its innovative cloud solutions for the life sciences industry. The company's strategic enhancements and robust financial results have garnered positive analyst ratings and promising future projections. With a solid track record of surpassing revenue expectations and delivering substantial returns, Veeva Systems is well-positioned for continued success.
However, Veeva Systems’ business is subject to a variety of risks and uncertainties, including agile competitors offering niche solutions, evolving regulations, increasing compliance costs, and macroeconomic factors like inflation impacting demand and costs. In addition, cybersecurity risks, incumbent inertia, and the rise of cloud-based solutions by competitors challenge Veeva to continuously innovate and enhance its cloud infrastructure to maintain its competitive edge.
